|
Preliminary Results of a Randomized Phase II Study Comparing the Efficacy of 2 Doses of Docetaxel (D) 100mg/m²/3 Weeks vs 75 mg/m²/3 Weeks in a Second Line Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC). |
| |
|
Stock and Other Ownership Interests - Ariane Medical Systems |
Consulting or Advisory Role - Ariane Medical Systems |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |